Log in

Relevant bibliographies by topics / Beta-blocker therapy / Journal articles

To see the other types of publications on this topic, follow the link: Beta-blocker therapy.

Journal articles on the topic 'Beta-blocker therapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Beta-blocker therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rezakovic, Saida, Mima Georgieva, and Lidija Pocanic. "Psorasis and beta-blocker therapy." Cardiologia Croatica 9, no. 9-10 (2014): 461. http://dx.doi.org/10.15836/ccar.2014.461.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Amadio, Peter, Doyle M. Cummings, and Patricia B. Amadio. "Beta-blocker therapy for hypertension." Postgraduate Medicine 82, no. 8 (1987): 152–59. http://dx.doi.org/10.1080/00325481.1987.11700083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Reeder, Sara Jones, and Rosemary L. Hoffmann. "Beta-blocker therapy for hypertension." Dimensions of Critical Care Nursing 20, no. 2 (2001): 2–9. http://dx.doi.org/10.1097/00003465-200103000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Beta-blocker therapy for hypertension." Dimensions of Critical Care Nursing 20, no. 2 (2001): 10. http://dx.doi.org/10.1097/00003465-200103000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Beta-blocker therapy for hypertension." Dimensions of Critical Care Nursing 20, no. 2 (2001): 11–12. http://dx.doi.org/10.1097/00003465-200103000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tuman, Kenneth J., and Robert J. McCarthy. "Individualizing beta-Adrenergic Blocker Therapy." Anesthesia & Analgesia 88, no. 3 (1999): 475–76. http://dx.doi.org/10.1213/00000539-199903000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tuman, Kenneth J., and Robert J. McCarthy. "Individualizing beta-Adrenergic Blocker Therapy." Anesthesia & Analgesia 88, no. 3 (1999): 475–76. http://dx.doi.org/10.1097/00000539-199903000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Alsagaff, Mochamad Yusuf, Melly Susanti, Mochammad Thaha, and Christian Jonatan. "Inotropes in Chronic Beta-Blocker Therapy." Pharmacognosy Journal 13, no. 3 (2021): 828–34. http://dx.doi.org/10.5530/pj.2021.13.105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Poldermans, Don, and Eric Boersma. "Beta-Blocker Therapy in Noncardiac Surgery." New England Journal of Medicine 353, no. 4 (2005): 412–14. http://dx.doi.org/10.1056/nejme058076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Yang, Bennie, and Jasmine Luzum. "Pharmacogenetic Considerations in Beta-Blocker Therapy." SMART-MD Journal of Precision Medicine 1, no. 2 (2024): e9-e13. http://dx.doi.org/10.69734/hpaezm84.

Full text

Abstract:

Pharmacogenetic testing offers a promising approach to personalizing beta-blocker therapy which is used for a variety of diseases, such as heart failure, myocardial infarction and migraine prophylaxis. The genetic variability in the metabolism and response to beta-blockers such as metoprolol can significantly influence treatment outcomes. Understanding these genetic differences can help optimize therapy and minimize adverse effects. A brief summary of the current guideline and recommendations: Approximately 0.3-6.5% (depending on their ancestry) of patients are CYP2D6 poor metabolizers. CYP2D6

APA, Harvard, Vancouver, ISO, and other styles

11

Cataldo Miranda, Pilar, Danijela Gasevic, Caroline Trin, et al. "Beta-Blocker Therapy After Myocardial Infarction." JACC: Advances 4, no. 3 (2025): 101582. https://doi.org/10.1016/j.jacadv.2024.101582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Grandi, Eleonora, and Crystal M. Ripplinger. "Antiarrhythmic mechanisms of beta blocker therapy." Pharmacological Research 146 (August 2019): 104274. http://dx.doi.org/10.1016/j.phrs.2019.104274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Faxon, David P. "Beta-blocker therapy and primary angioplasty." Journal of the American College of Cardiology 43, no. 10 (2004): 1788–90. http://dx.doi.org/10.1016/j.jacc.2004.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Golden, Robert N., and Dwight L. Evans. "Beta-blocker therapy and clinical depression." American Journal of Medicine 84, no. 3 (1988): 559–60. http://dx.doi.org/10.1016/0002-9343(88)90285-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

GRONEFELD, GERIAN C., and STEFAN H. HOHNLOSER. "beta-Blocker Therapy in Atrial Fibrillation." Pacing and Clinical Electrophysiology 26, no. 7p2 (2003): 1607–12. http://dx.doi.org/10.1046/j.1460-9592.2003.t01-1-00239.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Taqueti, Viviany R., and Patrick T. O’Gara. "Beta-Blocker Therapy After Myocardial Infarction." Journal of the American College of Cardiology 66, no. 13 (2015): 1442–44. http://dx.doi.org/10.1016/j.jacc.2015.08.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Kulbachinskaya, E. K., L. S. Gordeev, and V. V. Bereznitskaya. "Propafenone in combination antiarrhythmic therapy for patients with catecholaminergic polymorphic ventricular tachycardia." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 70, no. 1 (2025): 42–49. https://doi.org/10.21508/1027-4065-2025-70-1-42-49.

Full text

Abstract:

Summary. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited channelopathy characterized by bidirectional and/or polymorphic ventricular tachycardia triggered by physical or emotional stress. CPVT is associated with a high mortality rate if left untreated. Although beta-blockers are the cornerstone of pharmacologic management for catecholaminergic polymorphic ventricular tachycardia, their efficacy as monotherapy is often limited. This limitation highlights the need to investigate combination antiarrhythmic therapies that may more effectively reduce the risk of arrhyth

APA, Harvard, Vancouver, ISO, and other styles

18

ZHAO, Ying-xin, Yue-ping LI, Fei GAO, et al. "Heart rate distribution and predictors of resting heart rate after initiation of beta-blocker treatment in patients with coronary artery disease: REsults of Sympathetic Evaluation And Research of China (RESEARCH) study." Chinese Medical Journal 126, no. 18 (2013): 3460–63. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20130859.

Full text

Abstract:

Background The importance of heart rate as secondary prevention strategies for patients with coronary artery disease (CAD) is emphasized by multiple guidelines. However, limited information is available on the heart rate distribution and the change patterns of resting heart rate when initiating beta-blocker therapy among Chinese patients with CAD. Methods The REsults of Sympathetic Evaluation And Research of China (RESEARCH) study is a multi-centre, prospective, observational study involving 147 centers in 23 cities across China. All eligible beta-blocker naive patients were prescribed with me

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Beta-blocker and Exercise Capacity." Medicine & Science in Sports & Exercise 41, no. 7 (2009): 1532. http://dx.doi.org/10.1249/mss.0b013e3181aaed04.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Gläser, Sven, Christoph Schäper, Ralf Ewert, Beate Koch, Henry Völzke, and Christian F. Opitz. "Beta-Blocker and Exercise Capacity." Medicine & Science in Sports & Exercise 41, no. 4 (2009): 967. http://dx.doi.org/10.1249/mss.0b013e3181af696.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kumar, Ambuj, Amandeep Kumar, Pankaj Kumar Singh, Shashwat Mishra, Kanwaljeet Garg, and Bhawani S. Sharma. "Letter to the Editor: Beta-blocker therapy." Journal of Neurosurgery 126, no. 3 (2017): 1026–27. http://dx.doi.org/10.3171/2016.10.jns162509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

ARBABI, SAMAN. "BETA-BLOCKER THERAPY IN THE INJURED PATIENT." Shock 21, Supplement (2004): 60. http://dx.doi.org/10.1097/00024382-200403001-00237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Raebel, Marsha A. "Potentiated Anaphylaxis during Chronic Beta-Blocker Therapy." Drug Intelligence & Clinical Pharmacy 22, no. 9 (1988): 720–21. http://dx.doi.org/10.1177/106002808802200919.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Inomata, Takayuki. "How to Undertake the Beta-Blocker Therapy." Journal of Cardiac Failure 11, no. 9 (2005): S242. http://dx.doi.org/10.1016/j.cardfail.2005.08.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Yang, Yanhua, Suxia Guo, Ziyao Huang, et al. "Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation." Cardiology Research and Practice 2020 (May 13, 2020): 1–7. http://dx.doi.org/10.1155/2020/3059864.

Full text

Abstract:

Background. There are no proven effective treatments that can reduce the mortality in heart failure with preserved ejection fraction (HFpEF), probably due to its heterogeneous nature which will weaken the effect of therapy in clinical studies. We evaluated the effect of beta-blocker treatment in HFpEF patients associated with atrial fibrillation (AF), which is a homogeneous syndrome and has seldom been discussed. Methods. This retrospective cohort study screened 955 patients diagnosed with AF and HFpEF. Patients with a range of underlying heart diseases or severe comorbidities were excluded; 1

APA, Harvard, Vancouver, ISO, and other styles

26

Dalvi, Naina P., Apeksha A. Gala, Sunil K. Gvalani, and Sourav Mahajan. "A Case of suspected Sick Sinus Syndrome due to combined Beta-blocker and Calcium Channel Blocker Therapy: Anesthesia Management." Journal of Research & Innovation in Anesthesia 2, no. 2 (2017): 68–70. http://dx.doi.org/10.5005/jp-journals-10049-0036.

Full text

Abstract:

ABSTRACT Sick sinus syndrome (SSS) is a generalized abnormality of cardiac impulse formation. Abnormalities encompassed by this syndrome may include inappropriate sinus bradycardia, sinus arrest, bradyarrhythmias, or tachyarrhythmias. We present a case of a 54-year-old hypertensive male posted for L4–L5 decompression, whom we suspected to develop SSS due to overdose of combined beta-blocker (BB) and calcium channel blocker (CCB) therapy. How to cite this article Gala AA, Dalvi NP, Gvalani SK, Mahajan S. A Case of suspected Sick Sinus Syndrome due to combined Beta-blocker and Calcium Channel Bl

APA, Harvard, Vancouver, ISO, and other styles

27

Joo, Seung-Jae. "Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it." Acute and Critical Care 38, no. 3 (2023): 251–60. http://dx.doi.org/10.4266/acc.2023.00955.

Full text

Abstract:

Most of the evidences for beneficial effects of beta-blockers in patients with acute myocardial infarction (AMI) were from the clinical studies published in the pre-reperfusion era when anti-platelet drugs, statins or inhibitors of renin-angiotensin-aldosterone system which are known to reduce cardiovascular mortality of patients with AMI were not introduced. In the reperfusion era, beta-blockers’ benefit has not been clearly shown except in patients with reduced ejection fraction (EF; ≤40%). In the era of the early reperfusion therapy for AMI, a number of patients with mildly reduced EF (>

APA, Harvard, Vancouver, ISO, and other styles

28

Eisele, George, Linda L. Gilmore, and Edward B. Blanchard. "Close Clinical Observation Minimizes the Complications of Beta-Blocker Withdrawal." Annals of Pharmacotherapy 28, no. 7-8 (1994): 849–51. http://dx.doi.org/10.1177/106002809402800704.

Full text

Abstract:

OBJECTIVE: To determine whether beta-blocker withdrawal under close medical supervision poses undue risks. DESIGN: Retrospective case review. Data extracted from previous study. SUBJECTS: 114 hypertensive subjects tapered from beta-blocker therapy. Subjects were a subset of patients originally studied for blood pressure medication withdrawal and biofeedback training. MAIN OUTCOME MEASURES: Frequency of symptoms and adverse effects reported by subjects during medication taper to the study nurse. RESULTS: Symptoms were no more likely to occur with beta-blocker withdrawal than with withdrawal of

APA, Harvard, Vancouver, ISO, and other styles

29

van Klei, Wilton A., Gregory L. Bryson, Homer Yang та Alan J. Forster. "Effect of β-blocker Prescription on the Incidence of Postoperative Myocardial Infarction after Hip and Knee Arthroplasty". Anesthesiology 111, № 4 (2009): 717–24. http://dx.doi.org/10.1097/aln.0b013e3181b6a761.

Full text

Abstract:

Background American College of Cardiology/American Heart Association guidelines recommend beta-blockade for selected low- and intermediate-risk noncardiac surgery patients. The authors evaluated the effect of perioperative beta-blockade on postoperative myocardial infarction (POMI) in low-risk patients undergoing intermediate-risk surgery. Methods Patients who underwent elective hip or knee arthroplasty between January 1, 2002 and June 30, 2006 were identified. POMI was defined as a Troponin T value of more than 0.1 ng . ml(-1). Patients were divided into three groups: those prescribed a beta-

APA, Harvard, Vancouver, ISO, and other styles

30

Engebretsen, Kristin M., Kathleen M. Kaczmarek, Jenifer Morgan, and Joel S. Holger. "High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning." Clinical Toxicology 49, no. 4 (2011): 277–83. http://dx.doi.org/10.3109/15563650.2011.582471.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Günaydın, Y. K., O. Özelbaykal, H. Ş. Akça, et al. "Intravenous lipid emulsion therapy in calcium channel blocker and beta-blocker poisoning." Notfall + Rettungsmedizin 20, no. 1 (2016): 54–60. http://dx.doi.org/10.1007/s10049-016-0225-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Hwa, Yi Lisa, Martha Q. Lacy, Morie A. Gertz, et al. "Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients." Blood 124, no. 21 (2014): 4751. http://dx.doi.org/10.1182/blood.v124.21.4751.4751.

Full text

Abstract:

Abstract Background: A recent preclinical study revealed an antiproliferative and apoptotic effect of propranolol on MM cell lines. This study was to investigate if propranolol and other beta blocker intake improved survival in MM patients. Methods: Among patients seen at Mayo Clinic, Rochester from 1993 to 2010, we identified those taking propranolol. Age, year of diagnosis, International Staging System (ISS), Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) were used as case-match variables to match propranolol users to two control populations: no beta blocker and other beta-

APA, Harvard, Vancouver, ISO, and other styles

33

Mooss, Aryan N., Daniel E. Hilleman, Syed M. Mohiuddin, and Claire B. Hunter. "Safety of Esmolol in Patients with Acute Myocardial Infarction Treated with Thrombolytic Therapy Who Had Relative Contraindications to Beta-Blocker Therapy." Annals of Pharmacotherapy 28, no. 6 (1994): 701–3. http://dx.doi.org/10.1177/106002809402800601.

Full text

Abstract:

OBJECTIVE: This study was conducted to evaluate the safety of esmolol in 114 patients treated with thrombolytic therapy for acute myocardial infarction who also had relative contraindications to beta-blockade, and the predictive value of patient tolerance to esmolol and subsequent patient tolerance of oral beta-blocker therapy. PATIENTS: One hundred and fourteen patients with myocardial infarction documented by enzyme concentrations and electrocardiographic changes who also had relative contraindications to beta-blockade. METHODS: Esmolol was initiated during acute myocardial infarction for my

APA, Harvard, Vancouver, ISO, and other styles

34

Beckman, Kenneth A., Luis Chanes, and Stephen R. Kaufman. "Lichen Planus Associated With Topical Beta-Blocker Therapy." American Journal of Ophthalmology 120, no. 4 (1995): 530–31. http://dx.doi.org/10.1016/s0002-9394(14)72671-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Biccard, B. M., J. W. Sear, and P. Foex. "The pharmacoeconomics of peri-operative beta-blocker therapy." Anaesthesia 61, no. 1 (2006): 4–8. http://dx.doi.org/10.1111/j.1365-2044.2005.04401.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Tomcsányi, János, András Wettstein, Emil Toldy-Schedel, and Miklós Somlói. "Switching beta-blocker therapy in chronic heart failure." International Journal of Cardiology 130, no. 3 (2008): 497–99. http://dx.doi.org/10.1016/j.ijcard.2007.07.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Abbott, Alison. "Beta-blocker goes on trial as asthma therapy." Nature 432, no. 7013 (2004): 7. http://dx.doi.org/10.1038/432007a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Suzuki, Takeshi. "Beta blocker therapy in the intensive care unit." Journal of the Japanese Society of Intensive Care Medicine 26, no. 4 (2019): 249–58. http://dx.doi.org/10.3918/jsicm.26_249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Wang, Chun-Chieh, San-Jou Yeh, Ming-Shien Wen, Fun-Chung Lin, and Delon Wu. "Worsening of Vasovagal Syncope After Beta-Blocker Therapy." Chest 106, no. 3 (1994): 963–65. http://dx.doi.org/10.1378/chest.106.3.963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Yasumura, Yoshio. "Who is the Responder to Beta-Blocker Therapy." Journal of Cardiac Failure 11, no. 9 (2005): S243. http://dx.doi.org/10.1016/j.cardfail.2005.08.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Gottanka, Johannes, Douglas H. Johnson, Peter Martus, and Elke Lütjen-Drecoll. "Beta-adrenergic blocker therapy and the trabecular meshwork." Graefe's Archive for Clinical and Experimental Ophthalmology 239, no. 2 (2001): 138–44. http://dx.doi.org/10.1007/s004170000231.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Al-Otaibi, Faisal. "A study on the prescription pattern of anti-hypertensive drugs in general hospital of Al-Quwayyah, Saudi Arabia." International Journal of Research in Pharmaceutical Sciences 9, no. 1 (2018): 154. http://dx.doi.org/10.26452/ijrps.v9i1.1217.

Full text

Abstract:

An open, non-comparative, observational study conducted on hypertensive patients attending the OPD medicine of Al-Quwayyah general hospital, Al-Quwayyah, Saudi Arabia by conducting patient interviews and recording the data on drug utilization form based on JNC-7 and WHO format. Total of 212 hypertensive patients were included in study, prevalence of hypertension was found to be higher in male in age group of 45-59 years, smoker and pre-hypertension stage. 60.38% antihypertensive drugs prescribed by trade name and by 39.62 % by generic name. It was observed that Monotherapy were most prescribed

APA, Harvard, Vancouver, ISO, and other styles

43

Bereznitskaya, V. V., E. K. Kulbachinskaya, and M. A. Shkolnikova. "Clinical features and antiarrhythmic therapy in patients with catecholaminergic polymorphic ventricular tachycardia." Journal of Arrhythmology 28, no. 4 (2021): 62–69. http://dx.doi.org/10.35336/va-2021-4-62-69.

Full text

Abstract:

Aims. To evaluate the long-term efficacy of antiarrhythmic therapy in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT).Methods. CPVT was diagnosed in 11 patients between the ages of 3-12 years with a minimum follow-up of 10 years. The data analyzed was obtained from existing medical records that included symptoms, family screenings, treadmill tests, electrocardiography, echocardiography, implanted cardioverter-defibrillator data (ICD), and medical treatments.Results. Cardiac events were registered in 75% of patients on beta-blocker therapy. Supraventricular arrhythmia

APA, Harvard, Vancouver, ISO, and other styles

44

Jin, Suho, Kristin Kostka, Jose D. Posada, et al. "Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases." Journal of Personalized Medicine 10, no. 4 (2020): 288. http://dx.doi.org/10.3390/jpm10040288.

Full text

Abstract:

Incident depression has been reported to be associated with poor prognosis in patients with cardiovascular disease (CVD), which might be associated with beta-blocker therapy. Because early detection and intervention can alleviate the severity of depression, we aimed to develop a machine learning (ML) model predicting the onset of major depressive disorder (MDD). A model based on L1 regularized logistic regression was trained against the South Korean nationwide administrative claims database to identify risk factors for the incident MDD after beta-blocker therapy in patients with CVD. We identi

APA, Harvard, Vancouver, ISO, and other styles

45

Zineh, I., B. J. Puckett, D. F. Pauly, S. P. McGorray, and J. A. Johnson. "Beta-1 adrenoreceptor gene haplotypes and antihypertensive response to Beta-blocker therapy." Clinical Pharmacology & Therapeutics 73, no. 2 (2003): P97. http://dx.doi.org/10.1016/s0009-9236(03)90712-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Nemoto, Shinji, Yusuke Kasahara, Kazuhiro P. Izawa та ін. "Effects of αβ-Blocker Versus β1-Blocker Treatment on Heart Rate Response During Incremental Cardiopulmonary Exercise in Japanese Male Patients with Subacute Myocardial Infarction". International Journal of Environmental Research and Public Health 16, № 16 (2019): 2838. http://dx.doi.org/10.3390/ijerph16162838.

Full text

Abstract:

A simplified substitute for heart rate (HR) at the anaerobic threshold (AT), i.e., resting HR plus 30 beats per minute or a percentage of predicted maximum HR, is used as a way to determine exercise intensity without cardiopulmonary exercise testing (CPX) data. However, difficulties arise when using this method in subacute myocardial infarction (MI) patients undergoing beta-blocker therapy. This study compared the effects of αβ-blocker and β1-blocker treatment to clarify how different beta blockers affect HR response during incremental exercise. MI patients were divided into αβ-blocker (n = 67

APA, Harvard, Vancouver, ISO, and other styles

47

Colunga, Kayla N., and Justin P. Reinert. "A Review of Beta-Blocker Toxicity and Management Strategies." Senior Care Pharmacist 35, no. 8 (2020): 345–48. http://dx.doi.org/10.4140/tcp.n.2020.345.

Full text

Abstract:

In 2017, a total of 26,431 beta-blocker exposures were reported to United States poison centers, with 21% of adult exposures attributed to patients 60 years of age and older. Beta-blockers are a major component of therapy in numerous cardiovascular diseases, which have a higher incidence in older people. Along with polypharmacy and neurocognitive decline, potentially limiting reliable medication adherence, older patients may be more sensitive to the hypotensive and bradycardic effects of beta-blockers. Additionally, because of a lack of success of traditional management methods, evidence of ne

APA, Harvard, Vancouver, ISO, and other styles

48

Colunga, Kayla N., and Justin P. Reinert. "A Review of Beta-Blocker Toxicity and Management Strategies." Senior Care Pharmacist 35, no. 8 (2020): 345–48. http://dx.doi.org/10.4140/tcp.n.2020.345.

Full text

Abstract:

In 2017, a total of 26,431 beta-blocker exposures were reported to United States poison centers, with 21% of adult exposures attributed to patients 60 years of age and older. Beta-blockers are a major component of therapy in numerous cardiovascular diseases, which have a higher incidence in older people. Along with polypharmacy and neurocognitive decline, potentially limiting reliable medication adherence, older patients may be more sensitive to the hypotensive and bradycardic effects of beta-blockers. Additionally, because of a lack of success of traditional management methods, evidence of ne

APA, Harvard, Vancouver, ISO, and other styles

49

Müller, C., L. B. Mänhardt, C. Willaschek, E. M. Schneider, E. A. Stuth, and R. Buchhorn. "Beta-Blocker Therapy and Hemophagocytic Lymphohistiocytosis: A Case Report." Cardiology Research and Practice 2010 (2010): 1–4. http://dx.doi.org/10.4061/2010/912757.

Full text

Abstract:

Objective. The aim of this paper is to describe a fatal case of hemophagocytic lymphohistiocytosis (HLH) in a patient with severe heart failure, who was treated with low-dose propranolol.Patient and Interventions. We report on a 7-month-old boy with Downs syndrome who was born with an unbalanced, left dominant atrioventricular septal defect and aortic coarctation. Despite coarctation repair and pulmonary artery banding he developed intractable heart failure and fever of unknown origin. Since he remained in heart failure he received a trial of low-dose propranolol to stabilize his cardiopulmona

APA, Harvard, Vancouver, ISO, and other styles

50

Eber, Bernd, Karl-Heinz Tscheliessnigg, Michael Anelli-Monti, et al. "Aortic Dissection due to Discontinuation of Beta-Blocker Therapy." Cardiology 83, no. 1-2 (1993): 128–31. http://dx.doi.org/10.1159/000175959.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!